A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.


Updates from The Motley Fool

Latest updates on Novavax from Fool.com.  The Fool has written over 200 articles on Novavax.
Why Novavax Stock Buckled in June

Novavax's stock got blasted by geopolitical headwinds last month, but that doesn't mean it's now ...

3 Top Stocks Under $5

These low-priced stocks could generate huge returns. But there are huge risks, too.

Why Novavax Stock Spiked Today

Novavax's experimental flu vaccine hit the mark in a combined phase 1/2 trial in older adults.



Stock Performance

View Interactive NVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novavax.
Current Price: $2.03
Prev Close: $2.03
Open: $2.03
Bid: $2.01
Ask: $2.03
Day's Range: $1.96 - $2.04
52wk Range: $0.96 - $2.75
Volume: 3,162,104
Avg Vol 7,648,725
Market Cap: $637M
P/E (ttm): -3.62
EPS (ttm): -$0.56
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Novavax.
CAPS Rating 2 out of 5
 
312 Outperform
83 Underperform
CAPS All Stars
 
38 Outperform
16 Underperform

How do you think Novavax will perform against the market?



You pick for Novavax is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Stanley C. Erck, CEO

79% Approve

Based on 35 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novavax.

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers